Switch-DARPin Platform
Various Oncology Targets
Discovery/PreclinicalPlatform Development
Key Facts
Indication
Various Oncology Targets
Phase
Discovery/Preclinical
Status
Platform Development
Company
About Molecular Partners
Molecular Partners is a mission-driven biotech founded in 2004, focused on transforming the lives of patients with serious diseases through its innovative DARPin platform. The company has achieved clinical validation for its technology and is advancing a pipeline of next-generation oncology candidates, including tetra-specific T-cell engagers and logic-gated Switch-DARPins. Its strategy combines deep in-house R&D expertise with strategic collaborations to build a broad portfolio targeting high-unmet-need cancers.
View full company profileTherapeutic Areas
Other Various Oncology Targets Drugs
| Drug | Company | Phase |
|---|---|---|
| Oncology Pipeline | Jazz Pharmaceuticals | Pre-Clinical to Clinical |
| Radio-DARPin Platform | Molecular Partners | Discovery/Preclinical |